321 related articles for article (PubMed ID: 22472510)
1. Cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
[TBL] [Abstract][Full Text] [Related]
2. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
4. The Prostate cancer Research International: Active Surveillance study.
Bangma CH; Bul M; Roobol M
Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
[TBL] [Abstract][Full Text] [Related]
5. Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancer.
Klotz L
World J Urol; 2022 Jan; 40(1):1-8. PubMed ID: 33492425
[TBL] [Abstract][Full Text] [Related]
6. Psychological aspects of active surveillance.
van den Bergh RC; Korfage IJ; Bangma CH
Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
[TBL] [Abstract][Full Text] [Related]
8. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
9. The role of 5-alpha-reductase inhibitors in active surveillance.
Margel D; Fleshner N
Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance for prostate cancer: a review.
Klotz L
Arch Esp Urol; 2011 Oct; 64(8):806-14. PubMed ID: 22052761
[TBL] [Abstract][Full Text] [Related]
12. Overdiagnosis and overtreatment of early detected prostate cancer.
Bangma CH; Roemeling S; Schröder FH
World J Urol; 2007 Mar; 25(1):3-9. PubMed ID: 17364211
[TBL] [Abstract][Full Text] [Related]
13. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
14. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
15. Cancer, concepts, cohorts and complexity: avoiding oversimplification of overdiagnosis.
Detterbeck FC
Thorax; 2012 Sep; 67(9):842-5. PubMed ID: 22628119
[No Abstract] [Full Text] [Related]
16. Advances in the diagnosis and treatment of prostate cancer.
Kirby R
Practitioner; 2010 Feb; 254(1726):21, 23-4, 2. PubMed ID: 20307026
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
18. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.
Vis AN; Roemeling S; Reedijk AM; Otto SJ; Schröder FH
Eur Urol; 2008 Jan; 53(1):91-8. PubMed ID: 17583416
[TBL] [Abstract][Full Text] [Related]
19. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial results did not resolve controversies surrounding prostate cancer screening.
Hoffman RM
Curr Opin Urol; 2010 May; 20(3):189-93. PubMed ID: 20224414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
